No, no, not at all.
Actually, here's the bizarre solution that came out of this with Fabry. Because there are two drugs available, one of which got an NOC, one got an NOC/c, etc., it added some confusion to the whole situation.
What happens now is that all of the health ministries agreed to make the drug available through a research protocol. The research protocol then allows those patients who have been on the treatment through the clinical trials that have been done to get it approved to continue it. Now, the mother and son—and I think I know who you're talking about—are on the treatment. The son is actually in an expanded clinical trial, so he's getting the treatment through the clinical trial process.
What Canada came up with, then, is a separate research protocol to say, okay, for those patients who were not on the treatment previously, we're now going to give them a chance to go on the drug. First of all, they set standards that were very different from the international standards—much more stringent standards. So a lot of people who would qualify internationally for funding and treatment in their countries would never get it in Canada. But beyond that, what happened is that they said, we will now randomize you to one of those two drugs, and we will then see whether or not, over the long term, one drug is more effective than the other, etc.
So they've introduced this other research protocol.